Vyne Therapeutics Inc (VYNE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $19.07M
Last updated: Jul 27, 2026 at 5:00 PM ET
Vyne Therapeutics Inc (VYNE) Financials: Revenue, Profit and Cash Flow
Vyne Therapeutics reported revenue of $570.00K for the fiscal year ended Dec 31, 2025, up 13.8% from the year before. That year, net income was -$26.48M with a net margin of -4646.1%, operating cash flow was -$33.12M and free cash flow was -$33.12M. The quarter ended Mar 31, 2026 had revenue of $86.00K and net income of -$3.58M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $674.00K, a compound annual decline of 1.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $570.00K | +13.8% | 100.0% | -5219.1% | -4646.1% |
| Dec 2024 | $501.00K | +18.2% | 100.0% | -8710.0% | -7950.9% |
| Dec 2023 | $424.00K | -11.1% | 100.0% | -6900.5% | -6710.4% |
| Dec 2022 | $477.00K | -48.8% | 100.0% | -7189.7% | -4865.8% |
| Dec 2021 | $931.00K | -95.6% | 100.0% | -4179.5% | -7876.4% |
| Dec 2020 | $20.99M | +4638.8% | 93.4% | -1203.0% | -1217.4% |
| Dec 2019 | $443.00K | -87.7% | 100.0% | -21641.8% | -21484.9% |
| Dec 2018 | $3.60M | -21.5% | 100.0% | -2083.2% | -2062.9% |
| Dec 2017 | $4.58M | +579.8% | 100.0% | -645.9% | -634.6% |
| Dec 2016 | $674.00K | N/A | 100.0% | -2126.4% | -2087.2% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $570.00K | $501.00K | $424.00K | $477.00K | $931.00K | $20.99M | $443.00K | $3.60M | $4.58M | $674.00K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $1.39M | $0 | $0 | $0 | $0 |
| Gross profit | $570.00K | $501.00K | $424.00K | $477.00K | $931.00K | $19.60M | $443.00K | $3.60M | $4.58M | $674.00K |
| Research and development | $19.24M | $30.95M | $16.31M | $18.39M | $19.54M | $43.53M | $51.20M | $64.47M | $29.01M | $11.26M |
| Operating income | -$29.75M | -$43.64M | -$29.26M | -$34.30M | -$38.91M | -$252.55M | -$95.87M | -$74.89M | -$29.59M | -$14.33M |
| Net income | -$26.48M | -$39.83M | -$28.45M | -$23.21M | -$73.33M | -$255.57M | -$95.18M | -$74.16M | -$29.08M | -$14.07M |
| EBITDA | -$27.49M | -$42.24M | -$28.13M | -$33.86M | N/A | -$252.21M | -$94.08M | -$73.63M | -$29.52M | -$14.17M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $86.00K | $130.00K | $169.00K | $69.00K | $202.00K | $84.00K | $121.00K | $198.00K | $98.00K | $76.00K | $114.00K | $135.00K |
| Gross profit | $86.00K | $130.00K | $169.00K | $69.00K | $202.00K | $84.00K | $121.00K | $198.00K | $98.00K | $76.00K | $114.00K | $135.00K |
| Operating income | -$3.82M | -$5.22M | -$7.79M | -$7.54M | -$9.20M | -$12.77M | -$13.09M | -$10.40M | -$7.38M | -$6.83M | -$6.23M | -$10.32M |
| Net income | -$3.58M | -$4.84M | -$7.28M | -$5.75M | -$8.61M | -$12.02M | -$12.16M | -$9.41M | -$6.25M | -$6.19M | -$6.58M | -$10.06M |
Balance Sheet
As of Dec 2025, cash and equivalents of $24.03M were 79.7% of total assets of $30.16M, against total liabilities of $2.40M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $30.16M | $66.91M | $97.69M | $40.76M | $67.05M | $93.74M | $81.16M | $139.93M | $66.87M | $42.05M |
| Current assets | $30.01M | $64.44M | $95.96M | $38.27M | $63.19M | $87.26M | $76.41M | $139.50M | $63.86M | $31.54M |
| Cash and equivalents | $24.03M | $19.93M | $30.62M | $30.91M | $42.25M | $57.56M | $43.76M | $49.51M | $10.21M | $4.03M |
| Total liabilities | $2.40M | $14.82M | $8.95M | $9.35M | $18.41M | $56.25M | $63.58M | $9.55M | $14.57M | $12.49M |
| Short-term debt | N/A | $99.00K | $115.00K | N/A | $349.00K | $757.00K | $700.00K | N/A | $3.36M | $518.00K |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $33.17M | $32.73M | N/A | N/A | N/A |
| Shareholder equity | $27.77M | $52.09M | $88.73M | $31.20M | $48.64M | $37.49M | $17.57M | $130.38M | -$57.03M | -$29.44M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.87M | $30.16M | $36.13M | $44.72M | $56.42M | $66.91M | $76.20M | $86.65M | $91.68M | $97.69M | $19.27M | $24.96M |
| Total liabilities | $1.24M | $2.40M | $4.04M | $5.84M | $12.29M | $14.82M | $12.66M | $11.78M | $8.31M | $8.95M | $7.76M | $7.69M |
| Cash and equivalents | $24.63M | $24.03M | $19.35M | $22.05M | $28.21M | $19.93M | $16.27M | $29.61M | $19.07M | $30.67M | $15.45M | $20.63M |
| Shareholder equity | $24.64M | $27.77M | $32.09M | $38.88M | $44.13M | $52.09M | $63.54M | $74.87M | $83.37M | $88.73M | $11.51M | $17.27M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.12M | -$33.97M | -$25.34M | -$29.20M | -$56.37M | -$137.08M | -$73.39M | -$68.66M | -$28.22M | -$2.27M |
| Capital expenditures | $0 | $117.00K | $0 | $0 | $0 | $113.00K | $1.06M | $567.00K | $27.00K | $31.00K |
| Free cash flow | -$33.12M | -$34.09M | -$25.34M | -$29.20M | -$56.37M | -$137.19M | -$74.45M | -$69.23M | -$28.25M | -$2.30M |
| Dividends paid | N/A | N/A | N/A | N/A | $294.00K | N/A | $33.87M | N/A | N/A | N/A |
| Investing cash flow | $37.37M | $23.36M | -$57.35M | $15.67M | $1.03M | $89.11M | $41.87M | -$11.76M | -$15.09M | -$37.52M |
| Financing cash flow | -$143.00K | -$141.00K | $82.39M | $1.65M | $39.78M | $61.81M | $47.95M | $92.37M | $49.49M | $0 |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.08M | -$3.76M | -$7.10M | -$10.80M | -$11.46M | -$9.00M | -$8.51M | -$8.48M | -$7.98M | -$5.14M | -$5.15M | -$9.57M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $117.00K | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$4.08M | -$3.76M | -$7.10M | -$10.80M | -$11.46M | -$9.12M | -$8.51M | -$8.48M | -$7.98M | -$5.14M | -$5.15M | -$9.57M |
Frequently Asked Questions About VYNE
What is Vyne Therapeutics' annual revenue?
Vyne Therapeutics reported revenue of $570.00K for the fiscal year ended Dec 31, 2025.
How fast is Vyne Therapeutics' revenue growing?
Revenue was up 13.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 6.1%.
Is Vyne Therapeutics profitable?
No. Vyne Therapeutics reported net income of -$26.48M for the fiscal year ended Dec 31, 2025, with a net margin of -4646.1%.
How much free cash flow does VYNE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$33.12M minus capital expenditures of $0 produced free cash flow of -$33.12M.
How much debt does Vyne Therapeutics have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $24.03M.
VYNE pages: Overview, Financials